Logo image of EOLS

EVOLUS INC (EOLS) Stock Fundamental Analysis

NASDAQ:EOLS - Nasdaq - US30052C1071 - Common Stock - Currency: USD

5.9  -0.17 (-2.8%)

After market: 5.9 0 (0%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to EOLS. EOLS was compared to 193 industry peers in the Pharmaceuticals industry. EOLS may be in some trouble as it scores bad on both profitability and health. EOLS is not priced too expensively while it is growing strongly. Keep and eye on this one!


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year EOLS has reported negative net income.
EOLS had a negative operating cash flow in the past year.
In the past 5 years EOLS always reported negative net income.
In the past 5 years EOLS always reported negative operating cash flow.
EOLS Yearly Net Income VS EBIT VS OCF VS FCFEOLS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

EOLS's Return On Assets of -26.34% is in line compared to the rest of the industry. EOLS outperforms 56.48% of its industry peers.
Industry RankSector Rank
ROA -26.34%
ROE N/A
ROIC N/A
ROA(3y)-32.04%
ROA(5y)-38.45%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
EOLS Yearly ROA, ROE, ROICEOLS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 -400 -600 -800

1.3 Margins

Looking at the Gross Margin, with a value of 68.14%, EOLS is in the better half of the industry, outperforming 75.13% of the companies in the same industry.
In the last couple of years the Gross Margin of EOLS has declined.
EOLS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 68.14%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.76%
GM growth 5Y-2.34%
EOLS Yearly Profit, Operating, Gross MarginsEOLS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200

More info and screens

3

2. Health

2.1 Basic Checks

EOLS does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for EOLS has been increased compared to 1 year ago.
Compared to 5 years ago, EOLS has more shares outstanding
Compared to 1 year ago, EOLS has an improved debt to assets ratio.
EOLS Yearly Shares OutstandingEOLS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
EOLS Yearly Total Debt VS Total AssetsEOLS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

Based on the Altman-Z score of -1.85, we must say that EOLS is in the distress zone and has some risk of bankruptcy.
EOLS has a Altman-Z score (-1.85) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -1.85
ROIC/WACCN/A
WACC11%
EOLS Yearly LT Debt VS Equity VS FCFEOLS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

EOLS has a Current Ratio of 2.34. This indicates that EOLS is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of EOLS (2.34) is comparable to the rest of the industry.
A Quick Ratio of 2.16 indicates that EOLS has no problem at all paying its short term obligations.
The Quick ratio of EOLS (2.16) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 2.34
Quick Ratio 2.16
EOLS Yearly Current Assets VS Current LiabilitesEOLS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

7

3. Growth

3.1 Past

EOLS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -24.39%.
Looking at the last year, EOLS shows a very strong growth in Revenue. The Revenue has grown by 31.76%.
The Revenue has been growing by 50.14% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-24.39%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-500%
Revenue 1Y (TTM)31.76%
Revenue growth 3Y38.74%
Revenue growth 5Y50.14%
Sales Q2Q%3.71%

3.2 Future

EOLS is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 68.56% yearly.
Based on estimates for the next years, EOLS will show a very strong growth in Revenue. The Revenue will grow by 25.27% on average per year.
EPS Next Y49.41%
EPS Next 2Y112.55%
EPS Next 3Y95.22%
EPS Next 5Y68.56%
Revenue Next Year30.82%
Revenue Next 2Y31.99%
Revenue Next 3Y29.79%
Revenue Next 5Y25.27%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
EOLS Yearly Revenue VS EstimatesEOLS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 200M 400M 600M 800M 1B
EOLS Yearly EPS VS EstimatesEOLS Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 2 -2 4

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

EOLS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
The Price/Forward Earnings ratio is 9.37, which indicates a very decent valuation of EOLS.
Based on the Price/Forward Earnings ratio, EOLS is valued cheaply inside the industry as 83.42% of the companies are valued more expensively.
When comparing the Price/Forward Earnings ratio of EOLS to the average of the S&P500 Index (34.04), we can say EOLS is valued rather cheaply.
Industry RankSector Rank
PE N/A
Fwd PE 9.37
EOLS Price Earnings VS Forward Price EarningsEOLS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
EOLS Per share dataEOLS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3 4

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as EOLS's earnings are expected to grow with 95.22% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y112.55%
EPS Next 3Y95.22%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for EOLS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

EVOLUS INC

NASDAQ:EOLS (8/8/2025, 8:00:02 PM)

After market: 5.9 0 (0%)

5.9

-0.17 (-2.8%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-05 2025-08-05/amc
Earnings (Next)11-04 2025-11-04/amc
Inst Owners78.78%
Inst Owner Change0.14%
Ins Owners1.98%
Ins Owner Change0.47%
Market Cap380.43M
Analysts86.15
Price Target23.46 (297.63%)
Short Float %22.18%
Short Ratio12.58
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.12%
Min EPS beat(2)-0.95%
Max EPS beat(2)3.2%
EPS beat(4)2
Avg EPS beat(4)-8.51%
Min EPS beat(4)-60.88%
Max EPS beat(4)24.59%
EPS beat(8)5
Avg EPS beat(8)-9.96%
EPS beat(12)8
Avg EPS beat(12)-6.99%
EPS beat(16)11
Avg EPS beat(16)-1.96%
Revenue beat(2)0
Avg Revenue beat(2)-4.03%
Min Revenue beat(2)-6.96%
Max Revenue beat(2)-1.09%
Revenue beat(4)0
Avg Revenue beat(4)-3.03%
Min Revenue beat(4)-6.96%
Max Revenue beat(4)-0.28%
Revenue beat(8)3
Avg Revenue beat(8)-0.17%
Revenue beat(12)4
Avg Revenue beat(12)-0.97%
Revenue beat(16)7
Avg Revenue beat(16)0.2%
PT rev (1m)0%
PT rev (3m)-1.08%
EPS NQ rev (1m)-2.63%
EPS NQ rev (3m)4.41%
EPS NY rev (1m)4.62%
EPS NY rev (3m)-104.38%
Revenue NQ rev (1m)-0.17%
Revenue NQ rev (3m)-0.09%
Revenue NY rev (1m)0.03%
Revenue NY rev (3m)-0.76%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 9.37
P/S 1.38
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.51
EYN/A
EPS(NY)0.63
Fwd EY10.67%
FCF(TTM)-0.45
FCFYN/A
OCF(TTM)-0.36
OCFYN/A
SpS4.27
BVpS-0.1
TBVpS-1.2
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -26.34%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 68.14%
FCFM N/A
ROA(3y)-32.04%
ROA(5y)-38.45%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.76%
GM growth 5Y-2.34%
F-Score3
Asset Turnover1.29
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 91.46%
Cap/Sales 2.14%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.34
Quick Ratio 2.16
Altman-Z -1.85
F-Score3
WACC11%
ROIC/WACCN/A
Cap/Depr(3y)62.29%
Cap/Depr(5y)49.76%
Cap/Sales(3y)1.53%
Cap/Sales(5y)2.23%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-24.39%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-500%
EPS Next Y49.41%
EPS Next 2Y112.55%
EPS Next 3Y95.22%
EPS Next 5Y68.56%
Revenue 1Y (TTM)31.76%
Revenue growth 3Y38.74%
Revenue growth 5Y50.14%
Sales Q2Q%3.71%
Revenue Next Year30.82%
Revenue Next 2Y31.99%
Revenue Next 3Y29.79%
Revenue Next 5Y25.27%
EBIT growth 1Y12.25%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year823.46%
EBIT Next 3Y320.78%
EBIT Next 5Y226.63%
FCF growth 1Y59%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y65.8%
OCF growth 3YN/A
OCF growth 5YN/A